Junshi Biosciences (688180.SH): JT118 injection has been approved for clinical trials to prevent smallpox virus infection.

Zhicheng Finance and Economics APP news, Junshi Biosciences (688180.SH) announced that its controlling subsidiary Shanghai Junto BioMedicine Technology Co., Ltd. has received the "Drug Clinical Trial Approval Letter" issued by the National Medical Products Administration. The clinical trial application of JT118 injection has been approved, and the National Medical Products Administration has agreed to conduct clinical trials for preventing monkeypox virus infection.